Home
NKGen Biotech

NKGen Biotech Market Share Analysis for June 2026

NKGen Biotech is leveraging the power of a patient's immune system through the development of unique natural killer (NK) cell therapies.

Industry: N/A

Domainnkgenbiotech.com

Year Founded2002

Employees51 - 200

Annual Revenue$10M - $15M

NKGen Biotech

NKGen Biotech (including company regionals)

nkgenbiotech.com

See more website traffic and engagement information

NKGen Biotech Revenue up to June 2026 is 10M - 15M

revenue generated by NKGen Biotech top domains

NKGen Biotech top domains revenue over 3 years

Revenue for NKGen Biotech top domains

nkgenbiotech.com10M - 15M

See more with Sales Intelligence

Total visits to NKGen Biotech's top domains

Understand NKGen Biotech market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

nkgenbiotech.com3.9K

See more with Sales Intelligence

Avg. visit duration in NKGen Biotech's top domains

Analyze NKGen Biotech engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

nkgenbiotech.com00:00:19

See more with Sales Intelligence

Avg. pageviews on NKGen Biotech's top domains

See how NKGen Biotech keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

nkgenbiotech.com1.74

See more with Sales Intelligence

NKGen Biotech top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by NKGen Biotech

These are the website technologies, by industry, used by NKGen Biotech top domains

Social (3)

Instagram

Email Services (2)

Microsoft Exchange Online

Recruitment (2)

ADP

Advertising (1)

PubMatic

More Technologies

6

See all

News & Signals from NKGen Biotech

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsNKGen Biotech, Inc. attended event 2026 BIOCHINA Global Forum on Jul 9th '26.SANTA ANA, Calif., July 02, 2026 (GLOBE NEWSWIRE) - NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the Company's lead investigational program, troculeucel, at the 2026 BIOCHINA Global Forum, taking place July 9-10, 2026, in Seoul, South Korea.

NewsNKGen Biotech, Inc. is developing troculeucel.NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers.